Fujirebio Acquires ADx Neurosciences and Confirms Its Intentions to Bring Better and Earlier Neurodegenerative Disease Diagnostic Solutions to the Global Diagnostics Industry – Business Wire

Related Articles:

• Fujirebio Acquires ADx Neurosciences and Confirms Its Intentions to Bring Better and Earlier Neurodegenerative Disease Diagnostic Solutions to the Global Diagnostics Industry - Yahoo Finance June 23, 2022 Fujirebio Acquires ADx Neurosciences and Confirms Its Intentions to Bring Better and Earlier Neurodegenerative Disease Diagnostic Solutions to the Global Diagnostics Industry  Yahoo Finance
• The road ahead: 2022 January 20, 2022 # # # # The first post at the start of each year on the SoPD website tries to provide an overview of where things are in the search for ‘disease modifying’ therapies for Parkinson’s.  It is an exercise in managing expectations as well as discussing what research events are scheduled for the next year so that we can keep…
• HU Group's Fujirebio to acquire assays developer ADx NeuroSciences - Medical Device Network June 24, 2022 HU Group's Fujirebio to acquire assays developer ADx NeuroSciences  Medical Device Network
• The road ahead: 2021 January 25, 2021 # # # # At the start of each year, it is a useful practise to layout what is planned over the next 12 months. The events that are scheduled for the year to come, so that we can keep an eye out for them. Obviously, where 2021 will end actually is unpredictable, but an outline of what is scheduled…
• Fujirebio Europe Confirms Engagement in New Pathways for Alzheimer's Disease Research and Launches INNOTEST® Assays for the Two Promising Biomarkers NPTX2 and sTREM2 - Business Wire November 19, 2021 Fujirebio Europe Confirms Engagement in New Pathways for Alzheimer's Disease Research and Launches INNOTEST® Assays for the Two Promising Biomarkers NPTX2 and sTREM2  Business Wire
• The road ahead: 2020 January 5, 2020 Here at the SoPD, we are primarily interested in disease modification for Parkinson’s. While there is a great deal of interesting research exploring the causes of the condition, novel symptomatic therapies, and other aspects of Parkinson’s, my focus is generally on the science seeking to slow, stop or reverse the condition. At the start of each year, it is a…
• Monthly Research Review – May 2021 May 31, 2021 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during May 2021. The post is divided into 10 parts based on the type of research: Top 5 pieces of Parkinson’s news Articles of general interest Basic biology…
• 2020: Year in Review January 1, 2021 # # # # In this end-of-year post, we review the Parkinson’s research that caught our attention at SoPD HQ in 2020. Month-by-month we will briefly discuss some of the major pieces of research/ announcements that have defined the year and advanced our understanding of Parkinson’s. The list is based on nothing more than the author’s personal opinion – apologies…
• 2019: Year in review December 31, 2019   In this end-of-year post, we review the Parkinson’s research that caught our attention at SoPD HQ in 2019. Month-by-month we will briefly discuss some of the major pieces of research/announcements that have defined the year and advanced our understanding of Parkinson’s. The list is based on nothing more than the author’s personal opinion – apologies to any researchers who…
• Speech, Voice & Parkinson’s Q&A with John Dean January 28, 2021 We recently hosted a webinar with speech-language pathologist John Dean. You can get access to the recording here. We received so many questions during the session that we weren’t able to answer them all; so, John was kind enough to do some written Q&A for us. “When is a good time to start speech therapy?” It’s much better to maintain…
• ADepTing to the UCB-Novartis deal December 6, 2021 # # # # Alpha synuclein has long been viewed at “Public enemy #1” by the Parkinson’s research community. This sticky, abundant protein starts to cluster (or aggregate) in Parkinson’s. There have been several attempts to reduce levels of the protein floating around outside of cells (using “immunotherapy” approaches) But now clinical research is ramping up to determine if reducing…
• Our approach to failure February 14, 2021 # # # # Recently the results of two large clinical trials in Parkinson’s were announced. Both indicated that the therapies involved had not demonstrated any impact on the progression of Parkinson’s. This disappointing news resulted in the usual headlines (“Epic failure” & “Clinical trial tanks”) from news outlets whose editors have obviously never lost anyone they cared about. In…
• Planet Patient vs Planet Researcher: From Both Sides, Now June 27, 2018 “I cannot always control what goes on outside. But I can always control what goes on inside.” Wayne Dyer “Judge a man by his questions rather than his answers.” Voltaire Setting the Stage: This is Mariëtte Robijn-  She lives in the Netherlands and was diagnosed with Parkinson’s at the young age of 46.  Mariëtte has a dynamic and vibrant blog…
• Planet Patient vs Planet Researcher: From Both Sides, Now June 27, 2018 “I cannot always control what goes on outside. But I can always control what goes on inside.” Wayne Dyer “Judge a man by his questions rather than his answers.” Voltaire Setting the Stage: This is Mariëtte Robijn-  She lives in the Netherlands and was diagnosed with Parkinson’s at the young age of 46.  Mariëtte has a dynamic and vibrant blog…
• Planet Patient vs Planet Researcher: From Both Sides, Now June 27, 2018 “I cannot always control what goes on outside. But I can always control what goes on inside.” Wayne Dyer “Judge a man by his questions rather than his answers.” Voltaire Setting the Stage: This is Mariëtte Robijn-  She lives in the Netherlands and was diagnosed with Parkinson’s at the young age of 46.  Mariëtte has a dynamic and vibrant blog…
• ProMIS Neurosciences Develops Antibodies Targeting Toxic Forms of Alpha-Synuclein February 15, 2019 ProMIS Neurosciences has identified several antibody candidates that specifically target the toxic forms of alpha-synuclein, a key component of Lewy bodies that underlie the development of Parkinson’s disease. In vitro (in the lab) studies have shown that ProMIS’s antibody candidates for Parkinson’s disease have a high specificity for toxic forms of alpha-synuclein without binding to non-toxic essential forms of the protein. Moreover, these antibody candidates prevent…
• Repurposing bumetanide for Alzheimer’s October 15, 2021 # # # # Bumetanide (Bumex) is a diuretic drug (a medication that removes water, by increasing the production of urine). It is used to treat swelling caused by heart failure or liver or kidney disease. It is a widely used drug that has been well characterised in clinical use. Recently researchers conducted a screening study to identify clinically available…
• Bayer doubles down on Parkinson’s? December 10, 2020 # # # # News today of two biotech companies merging did not cause much of a ripple in the media, but the wider implications of the move are rather significant for Parkinson’s. Today it was announced that Brain Neurotherapy Bio (BNB) is going to merge with Asklepios Biopharmaceutical (aka AskBio). BNB are currently clinically testing a GDNF gene therapy…
• What Blockchains Can Do For Neurodegenerative Research March 6, 2021 “We become what we behold. We shape our tools, and thereafter our tools shape us.”― Marshall McLuhan In October 2008, one month after the American housing crisis sent a shock through the global financial system, a paper was published titled Bitcoin: A Peer-to-Peer Electronic Cash System. These nine fairly easy to read pages posted anonymously on an open forum birthed…
• Parkinson's Disease News - Editor's Picks (Archive 2016.11) March 17, 2017 Newsfeed: PD News PD Research News PD Fitness News PD Boxing News PD Web Articles PD Blogs PD Editor's Picks PD Twitter Newsfeed Neurons Paralyze Us During REM SleepIt will also be most useful in the study of Parkinson’s disease, since these pathologies are related. This work was published on December 12, 2016 on the website of the journal Brain.…
• 5 Ways to Live Well with Parkinson’s in 2019 January 8, 2019 It’s hard to ignore the feeling of newness in the air. The letting go of one year and welcoming in a new one and all of the possibilities it may provide. And, even if you’re not of fan of resolutions, you probably still have ideas of how you can live better in 2019. At the Davis Phinney Foundation, we certainly…
• Neurocognitive Predictors of Understanding of Intentions in Parkinson Disease. April 10, 2019 Related ArticlesNeurocognitive Predictors of Understanding of Intentions in Parkinson Disease. J Geriatr Psychiatry Neurol. 2019 Apr 08;:891988719841727 Authors: Kosutzka Z, Kralova M, Kusnirova A, Papayova M, Valkovic P, Csefalvay Z, Hajduk M Abstract OBJECTIVES: Theory of Mind (ToM), the ability to understand other people's mental states, is essential in everyday social interactions. The relationship between cognitive domains and ToM impairment…